Roth Capital Starts Concert Pharmaceuticals (CNCE) at Buy

March 19, 2014 9:14 AM EDT
Get Alerts CNCE Hot Sheet
Price: $8.37 --0%

Rating Summary:
    10 Buy, 5 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 2
Join SI Premium – FREE
Roth Capital initiates coverage on Concert Pharmaceuticals (NASDAQ: CNCE) with a Buy rating and a price target of $28.00.

For an analyst ratings summary and ratings history on Concert Pharmaceuticals click here. For more ratings news on Concert Pharmaceuticals click here.

Shares of Concert Pharmaceuticals closed at $14.10 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Hot New Coverage, New Coverage

Related Entities

Roth Capital